Cannabinoid for alcohol use disorder

Area of Science:

• Neuroscience
• Pharmacology
• Addiction Medicine

Background:

• The endocannabinoid system influences brain reward pathways and drug abuse.
• Cannabinoid receptors (CB1 and CB2) may modulate addiction properties.
• Cannabis and alcohol are frequently co-used, with potential implications for alcohol use disorder (AUD).

Purpose of the Study:

• To review evidence on the benefits and risks of combining alcohol and cannabis.
• To explore the therapeutic potential of cannabinoid compounds for AUD.
• To address the growing availability of cannabis due to legalization.

Main Methods:

• Literature review of existing studies on cannabis, alcohol, and the endocannabinoid system.
• Analysis of research on the co-use of alcohol and cannabis.
• Examination of preclinical and clinical data regarding cannabinoid therapies for AUD.

Main Results:

• Some evidence suggests cannabis may aid AUD treatment, acting as a substitute medication.
• Concomitant use of alcohol and cannabis can increase the risk of adverse outcomes.
• Cannabinoid compounds show promise, but risks associated with combined use require careful consideration.

Conclusions:

• The combination of alcohol and cannabis presents both potential therapeutic avenues and significant risks for AUD.
• Further research is needed to clarify the precise role of cannabinoids in AUD treatment and to mitigate risks of co-use.
• Cannabinoid-based therapies warrant investigation for AUD, balancing potential benefits against known risks.